• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker.

作者信息

Shimabukuro Michio

机构信息

Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University.

出版信息

J Atheroscler Thromb. 2023 Aug 1;30(8):853-854. doi: 10.5551/jat.ED227. Epub 2023 Feb 4.

DOI:10.5551/jat.ED227
PMID:36740275
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10406663/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9524/10406663/6a3d07b60456/30_ED227_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9524/10406663/6a3d07b60456/30_ED227_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9524/10406663/6a3d07b60456/30_ED227_1.jpg

相似文献

1
MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker.非酒精性脂肪性肝炎相关脂肪性肝病与动脉粥样硬化性心血管疾病：血浆肝素辅因子II活性作为抗肝纤维化生物标志物
J Atheroscler Thromb. 2023 Aug 1;30(8):853-854. doi: 10.5551/jat.ED227. Epub 2023 Feb 4.
2
Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.血浆肝素辅因子 II 活性与 2 型糖尿病非酒精性脂肪性肝病患者的肝纤维化呈负相关。
J Atheroscler Thromb. 2023 Aug 1;30(8):871-883. doi: 10.5551/jat.63752. Epub 2022 Oct 14.
3
Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.纤维化负担决定代谢功能障碍相关脂肪性肝病患者的心血管风险。
Gut Liver. 2022 Sep 15;16(5):786-797. doi: 10.5009/gnl210290. Epub 2022 Mar 24.
4
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.与代谢功能障碍相关的脂肪性肝病比非酒精性脂肪性肝病能更好地识别出具有心血管疾病风险的受试者。
Liver Int. 2023 Mar;43(3):608-625. doi: 10.1111/liv.15508. Epub 2023 Jan 11.
5
Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity.非酶糖基化降低肝素辅因子II的抗凝血酶活性。
Diabetologia. 1990 Apr;33(4):205-7. doi: 10.1007/BF00404797.
6
Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use.孕期及使用口服避孕药期间血浆中肝素辅因子II的活性
J Lab Clin Med. 1989 Dec;114(6):697-9.
7
Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.肝素的抗凝血酶活性。糖链长度对肝素辅因子II和抗凝血酶抑制凝血酶的影响。
Biochem J. 1989 Aug 15;262(1):225-32. doi: 10.1042/bj2620225.
8
Evidence for essential lysines in heparin cofactor II.肝素辅因子II中必需赖氨酸的证据。
Biochem Biophys Res Commun. 1984 Nov 14;124(3):745-51. doi: 10.1016/0006-291x(84)91021-0.
9
Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54).鉴定肝素辅因子II为戊聚糖多硫酸盐（SP54）抗凝血酶活性的主要血浆辅因子。
Thromb Res. 1984 Oct 15;36(2):187-94. doi: 10.1016/0049-3848(84)90340-2.
10
Heparin cofactor II is degraded by heparan sulfate and dextran sulfate.
Biochem Biophys Res Commun. 2015 Feb 20;457(4):585-8. doi: 10.1016/j.bbrc.2015.01.028. Epub 2015 Jan 16.

引用本文的文献

1
Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study.糖尿病足溃疡患者中代谢功能障碍相关脂肪性肝病与主要不良心血管和脑血管事件的关联：一项双向纵向队列研究
Diabetes Metab Syndr Obes. 2024 Mar 6;17:1119-1130. doi: 10.2147/DMSO.S447897. eCollection 2024.

本文引用的文献

1
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.代谢相关脂肪性肝病与心血管风险及疾病预防。
Cardiovasc Diabetol. 2022 Dec 3;21(1):270. doi: 10.1186/s12933-022-01697-0.
2
Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.血浆肝素辅因子 II 活性与 2 型糖尿病非酒精性脂肪性肝病患者的肝纤维化呈负相关。
J Atheroscler Thromb. 2023 Aug 1;30(8):871-883. doi: 10.5551/jat.63752. Epub 2022 Oct 14.
3
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.
非酒精性脂肪性肝病与心血管风险：美国心脏协会的科学声明
Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185. doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14.
4
Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences.非酒精性脂肪性肝病（NAFLD）患者的高凝状态：原因与后果
Biomedicines. 2022 Jan 24;10(2):249. doi: 10.3390/biomedicines10020249.
5
Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.从代谢相关脂肪性肝病或非酒精性脂肪性肝病的角度定义的脂肪性肝病患者发生心血管疾病的风险：日本一项回顾性全国索赔数据库研究。
J Gastroenterol. 2021 Nov;56(11):1022-1032. doi: 10.1007/s00535-021-01828-6. Epub 2021 Oct 3.
6
Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective.基于聚类分析的成年发病型糖尿病分类的血糖控制和预防糖尿病并发症的新策略：一个视角。
Diabetes Res Clin Pract. 2021 Oct;180:109067. doi: 10.1016/j.diabres.2021.109067. Epub 2021 Sep 23.
7
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义：国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
8
Procoagulant imbalance in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的促凝失衡。
J Hepatol. 2014 Jul;61(1):148-54. doi: 10.1016/j.jhep.2014.03.013. Epub 2014 Mar 18.
9
Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication.心脏脂肪过多与整体心脏代谢风险：新概念与临床意义。
Circ J. 2009 Jan;73(1):27-34. doi: 10.1253/circj.cj-08-1012. Epub 2008 Dec 4.
10
Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals.肝素辅因子II是老年个体中抗颈动脉粥样硬化的一种新型保护因子。
Circulation. 2004 Jun 8;109(22):2761-5. doi: 10.1161/01.CIR.0000129968.46095.F3. Epub 2004 May 17.